Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2016-04-08
- Target Recruit Count
- 60
- Registration Number
- NCT02722772
- Locations
- 🇨🇳
The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2016-04-22
- Target Recruit Count
- 60
- Registration Number
- NCT02722811
- Locations
- 🇨🇳
The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Anti-inflammatory Therapy to Improve Outcomes After TPIAT
- Conditions
- Interventions
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 44
- Registration Number
- NCT02713997
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 25
- Registration Number
- NCT02656082
- Locations
- 🇬🇧
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, United Kingdom
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1534
- Registration Number
- NCT02486302
- Locations
- 🇩🇪
Rheumatologisches MVZ Dresden GmbH im Gesundheitszentrum Dresden - Klotzsche (GZDK), Dresden, Sachsen, Germany
🇩🇪private practise Schmitt-Haendle, Bayreuth, Germany
🇩🇪private practise Hemmerich, Aachen, Germany
EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Johnny Ludvigsson
- Target Recruit Count
- 20
- Registration Number
- NCT02464033
- Locations
- 🇸🇪
Uddevalla Hospital, Uddevalla, Sweden
🇸🇪Helsingborg Hospital, Helsingborg, Sweden
🇸🇪Lund University Hospital, Lund, Sweden
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02464878
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Very Early Versus Delayed Etanercept in Patients With RA
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 120
- Registration Number
- NCT02433184
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 851
- Registration Number
- NCT02376790
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Treatments Against RA and Effect on FDG-PET/CT
- Conditions
- Interventions
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 159
- Registration Number
- NCT02374021
- Locations
- 🇺🇸
IRIS Research and Development, Plantation, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.